FibroGen's Roxadustat Aces Chemo-Induced Anemia Trial

  • FibroGen Inc FGEN has announced topline data from WHITNEY Phase 2 study of roxadustat for chemotherapy-induced anemia (CIA).
  • The trial met the primary efficacy endpoint of maximum change in hemoglobin within 16 weeks from baseline without red blood cell transfusion.
  • Related: After FDA Rejection, EMA Approves FibroGen-Astellas' Roxadustat In CKD-Associated Anemia
  • 92 patients with non-myeloid malignancy (solid tumor) having a hemoglobin level at or below 10 g/dL were enrolled in the trial.
  • Roxadustat was generally well tolerated, and there were no substantive differences in treatment-emergent adverse events (TEAEs) between arms with different starting doses.
  • The full results of the study will be presented at a medical meeting later this year.
  • Price Action: FGEN shares are down 0.21% at $12.08 during the market session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareSmall CapGeneralAnemiaBriefsPhase 2 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!